Over the past 30 years, Quotient Sciences has worked on over 3,000 molecules across all stages of development. SpeakPharma interviews Eleanor Row, our Executive Director of Commercial who discusses the challenges that drug developers should be aware of when trying to quickly get their molecule from discovery to investigational new drug (IND) stage - and onward into the clinic.
Eleanor also talks about how our integrated approach can help accelerate a molecule’s pathway to IND and beyond while sheding light on the different development functions at an early stage of drug development.
Read more of Eleanor's SpeakPharma interview on the Pharma Compass website by following the link below.